Saturday, June 20, 2020 10:06:23 AM
In my past projections I laid out Continent by Continent not just the USA. Although it's possible in the USA alone.
Doing what I do takes an open mind.
Ask yourself can the crackpot be right. Yes I can be.
What I did differently than just about any other broker was that I held my winners. Average holding period as a broker was 7 years.
A Buy Out in CYDY would be heart breaking. Sure; fast bucks. So what. I'm in this for 10 years or my untimely demise. I worked with brokers and all some looked for was the fast buck buy out.
Strong hands dreaded the buyout then and I do now.
Now run the Country by Country numbers. Sure, I don't know how Third World countries can buy our drug. Clinton Inc, Bill Gates. No idea. So our markets will be less in many countries verses the USA, Europe, Canada, Australia, New Zealand, too many to type.
I will say that 10% of Mexicans can afford our drug easier than the vast majority of Americans. The other 90% of Mexicans? No. That's for Bill Gates. I do not expect this.
If you want to live you will order our drug.
If you have not been on such train trips and you think I my possible outcomes for CYDY are out of reach. Just open your mind.
Can I be wrong and it only goes to 100$. Sure. There a whole deck of cards that have not been played. If the cards are played correctly, if good fortune hits in order, if our street fighter stays in control?? We have a great shot at 1000$ in ten years and much more in 20 to 30 years. CYDY is a future cash cow.
We will command a superior PE Ratio and a higher than industry average sale to total market cap ratio. CYDY will lead a revolution in medical practices. CYDY will be famous and anyone in it now can say they were there before it all happened.
To hold CYDY shares will demand a Big Picture. You will be tempted to sell for a thousand reasons. With the Big Picture you will expect 100$ and not be surprised. You will expect 500$, 1000$
Ride the train. Those that only want 30$ Great, sell in the 30$ range. It's your Big Picture.
Doing what I do takes an open mind.
Ask yourself can the crackpot be right. Yes I can be.
What I did differently than just about any other broker was that I held my winners. Average holding period as a broker was 7 years.
A Buy Out in CYDY would be heart breaking. Sure; fast bucks. So what. I'm in this for 10 years or my untimely demise. I worked with brokers and all some looked for was the fast buck buy out.
Strong hands dreaded the buyout then and I do now.
Now run the Country by Country numbers. Sure, I don't know how Third World countries can buy our drug. Clinton Inc, Bill Gates. No idea. So our markets will be less in many countries verses the USA, Europe, Canada, Australia, New Zealand, too many to type.
I will say that 10% of Mexicans can afford our drug easier than the vast majority of Americans. The other 90% of Mexicans? No. That's for Bill Gates. I do not expect this.
If you want to live you will order our drug.
If you have not been on such train trips and you think I my possible outcomes for CYDY are out of reach. Just open your mind.
Can I be wrong and it only goes to 100$. Sure. There a whole deck of cards that have not been played. If the cards are played correctly, if good fortune hits in order, if our street fighter stays in control?? We have a great shot at 1000$ in ten years and much more in 20 to 30 years. CYDY is a future cash cow.
We will command a superior PE Ratio and a higher than industry average sale to total market cap ratio. CYDY will lead a revolution in medical practices. CYDY will be famous and anyone in it now can say they were there before it all happened.
To hold CYDY shares will demand a Big Picture. You will be tempted to sell for a thousand reasons. With the Big Picture you will expect 100$ and not be surprised. You will expect 500$, 1000$
Ride the train. Those that only want 30$ Great, sell in the 30$ range. It's your Big Picture.
Recent CYDY News
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
